Torbjörn Sköld Appointed New CEO of Stille AB

Stille AB (publ) announces the board of director’s decision to appoint Torbjörn Sköld as the new CEO of Stille AB. Torbjörn Sköld has long experience from leading positions where the last 20 years have been within Life science with a primary focus on orthopedics and neurosurgery. The board of directors sees Torbjörns background and experience as great value, and he is well-suited to further enhance Stille’s strategy and increase shareholder value.

Torbjörn will begin his tenure on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company’s CEO since April 1st, 2019. Torbjörn comes most recently from De Puy Synthes EMEA, a Johnson & Johnson company, where he has been Vice President.

Lars Kvarnhem, chairman of the board comments today’s announcement: “First, I would like to thank Hanna Ernestam Wilkman for her contributions to the company. Hanna has formed a professional organization and managed to lead the company over the past years which have been particularly challenging considering the COVID-19 pandemic. I am very happy to have been able to recruit Torbjörn to become Stille’s new CEO. Torbjörn has a long experience of leading MedTech companies and has substantial experience in international sales and leadership, which suits Stille well.”

Torbjörn Sköld comments the appointment: “I really look forward to becoming the CEO of Stille. The company has an exciting future ahead with great growth potential within both its business units. The company has a strong brand, premium products, and a clear strategy.”

Torshälla, January 19th, 2023.

This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on January 19th, 2023, kl. 14.40 (CET).